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Abstract
Objective To systematically review the effect of folic acid based
homocysteine lowering on cardiovascular outcomes in people with kidney
disease.
Design Systematic review and meta-analysis.
Data sources Medline, Embase, the Cochrane Library, and
ClinicalTrials.gov to June 2011.
Study selection Randomised trials in people with non-dialysis dependent
chronic kidney disease or end stage kidney disease or with a functioning
kidney transplant reporting at least 100 patient years of follow-up and
assessing the effect of folic acid based homocysteine lowering therapy.
No language restrictions were applied.
Data extraction Two reviewers independently extracted data on study
setting, design, and outcomes using a standardised form. The primary
endpoint was cardiovascular events (myocardial infarction, stroke, and
cardiovascular mortality, or as defined by study author). Secondary
endpoints included the individual composite components, all cause
mortality, access thrombosis, requirement for renal replacement therapy,
and reported adverse events, including haematological and neurological
events. The effect of folic acid based homocysteine lowering on outcomes
was assessed with meta-analysis using random effects models.
Results 11 trials were identified that reported on 4389 people with
chronic kidney disease, 2452 with end stage kidney disease, and 4110
with functioning kidney transplants (10 951 participants in total). Folic
acid based homocysteine therapy did not prevent cardiovascular events
(relative risk 0.97, 95% confidence interval 0.92 to 1.03, P=0.326) or
any of the secondary outcomes. There was no evidence of heterogeneity
in subgroup analyses, including those of kidney disease category,
background fortification, rates of pre-existing disease, or baseline
homocysteine level. The definitions of chronic kidney disease varied
widely between the studies. Non-cardiovascular events could not be
analysed as few studies reported these outcomes.
Conclusions Folic acid based homocysteine lowering does not reduce
cardiovascular events in people with kidney disease. Folic acid based
regimens should not be used for the prevention of cardiovascular events
in people with kidney disease.
Introduction
People with kidney disease of any severity experience excess
cardiovascular events and mortality compared with the general
population. High plasma homocysteine levels increase as
estimated glomerular filtration rate levels decline with the
prevalence of hyperhomocysteinaemia (defined in relation to
the upper limit of the reference range), reported to be 36-89%
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RESEARCHinpatientswithchronickidneydiseasedependingonseverity,
1-3
70-75% in those with functioning kidney transplants,
4 5 and
85-100% in those with end stage kidney disease.
6-10 High
homocysteine levels have been associated with an increased
risk of cardiovascular events
11 in the general population, with
a 25% lower homocysteine level associated with an 11% lower
risk of coronary artery disease and a 19% lower risk of stroke.
12
The direct relation between homocysteine levels and
cardiovascular events observed in the general population has
led to the hypothesis that reducing homocysteine levels could
reduce the burden of cardiovascular disease. However, studies
of homocysteine lowering in the general population have failed
to show clear cardiovascular benefits.
13-16 Moreover, one study
inpeoplewithahistoryofmyocardialinfarctionsuggestedharm
withuseofacombinationoffolicacid,vitaminB12,andvitamin
B6.
13
The lack of benefit in the general population contrasts with that
seen in people with homocysteinuria, where therapy prevents
cardiovascular events.
17 A key distinction between the two
populations is the level of homocysteine, which is noticeably
higher (100-400 µmol/L) in people with homocysteinuria than
in people with cardiovascular disease or diabetes (mean 13
µmol/L
13 14 18). Homocysteine levels in people with kidney
disease lie between those of the general population and those
with classic homocysteinuria.
19 This has led to the hypothesis
thathomocysteineloweringmaybeusefulinpeoplewithkidney
disease, despite the lack of benefit in the broader population,
and has driven the conduct of randomised trials in this patient
group. A meta-analysis of eight large trials using individual
patient level data found the lack of effect of homocysteine
lowering to be consistent across categories of renal function.
20
That study utilised serum creatinine levels rather than an
estimate of glomerular filtration rate to assess renal function
and compared the impact of relatively mild differences in renal
function (serum creatinine concentrations <80, 80-94, and ≥95
µmol/L).
Weundertookasystematicreviewandmeta-analysistoexamine
theeffectsoffolicacidbasedhomocysteineloweringcompared
withplaceboorcontroltreatmentsoncardiovasculareventsand
other clinical outcomes in people with a range of severity of
kidneydisease,includingkidneytransplantrecipientsandthose
with non-dialysis dependent chronic kidney disease and end
stage kidney disease.
Methods
A systematic review of the literature was carried out according
to PRISMA
21guidelines for the conduct of meta-analyses of
interventiontrials.WesearchedMedlineviaOvid(1950toJune
2011), Embase (1966 to June 2011), and the Cochrane Library
database (Cochrane central register of controlled trials), using
relevant text words and medical subject headings that included
all spellings of homocysteine, folic acid, vitamin B,
cardiovasculardisease,kidneydisease,renaldialysis,andkidney
transplantation(seesupplementaryfileforsearchstrategy).The
searchwaslimitedtorandomisedclinicaltrialsinanylanguage.
To identify any other relevant studies we manually scanned the
reference lists of identified trials and review articles and
searched the clinicaltrials.gov website for additional studies.
Whennecessarywecontactedauthorsorprincipalinvestigators
for original data.
Study selection
Tworeviewers(MJJ,AK)independentlysearchedtheliterature,
extracted data, and assessed the quality of trials using a
standardised approach and a prespecified protocol (available
from the corresponding author). We considered for inclusion
all completed randomised controlled trials assessing the effects
of folic acid based homocysteine lowering therapy on
cardiovascular outcomes in people with kidney disease
(including those receiving maintenance dialysis or with a
functioning kidney transplant) and with a minimum of 100
patientyearsoffollow-up.Studieswithasequentialorcrossover
design were excluded. We considered studies to be eligible if
theycomparedfolicacidbasedhomocysteineloweringtherapy
with placebo or usual care or if they compared a higher dose of
folic acid based homocysteine lowering therapy with a lower
dose.ChronickidneydiseasewasdefinedastheNationalKidney
Foundation kidney disease outcomes quality initiative chronic
kidney disease stage 3-4 (that is, an estimated glomerular
filtration rate of 15-59 mL/min/1.73 m
2), or as defined by study
authors. End stage kidney disease was defined as an estimated
glomerular filtration rate of less than 15 mL/min/1.73 m
2, the
requirement for dialysis, or as defined by study authors. A
functioningkidneytransplantwasdefinedasakidneytransplant
in situ with no requirement for maintenance dialysis. The
outcomes assessed were prespecified, and included
cardiovascularevents(definedasmyocardialinfarction,stroke,
and cardiovascular death), all cause mortality, cardiovascular
mortality,myocardialinfarction,stroke,legamputation,dialysis
access thrombosis, and the start of renal replacement therapy
amongparticipantsnotrequiringdialysis.Dataonadverseevents
were collected, including gastrointestinal, dermatological,
neurological, and malignant events.
Data extraction and quality assessment
Using a standardised form two reviewers (MJJ, AK) extracted
data on participant characteristics (age, sex, study population,
severity of kidney disease, presence of diabetes, or history of
cardiacdisease,definedaspreviousmyocardialinfarctionoras
definedbystudyauthors),interventioncharacteristics,baseline
and achieved mean homocysteine levels, mean duration of
follow-up,andnumbersofoutcomeevents.Datawereextracted
according to intention to treat principles. One study in people
with functioning renal transplants reported both intention to
treat analyses and analyses censored for loss of transplant
function,
22 therefore we used the intention to treat data in these
analyses. The quality of the study report was determined by
assessing concealment of treatment allocation; blinding of
outcome assessors, care providers, and participants;
completeness of study and follow-up; and intention to treat
analysis.
23 Potential small study bias was assessed with the
Harbord test
24 and represented graphically with Begg funnel
plots of the natural log of the relative risk versus its standard
error.
25 Disagreements on abstracted data were resolved by
consensus and involvement of a third reviewer (VP) when
necessary.
Data synthesis and analysis
Weobtainedsummaryestimatesofoverallandsubgrouprelative
risk ratios using a random effects model. Analyses were done
withthemetancommandusingreportedraweventcountswhere
possible, or otherwise using reported relative risk estimates.
TheI
2statisticwasusedtoestimatethepercentageofvariability
across studies attributable to heterogeneity beyond chance.
26
Subgroup heterogeneity was estimated by the Cochran C test,
with studies weighted using the inverse variance method.
Prespecifiedsubgroupanalysesincludedclassificationofkidney
disease, study intervention (folic acid alone versus folic acid
plus B group vitamins), baseline homocysteine level (more or
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RESEARCHless than 20 µmol/L, the approximate 95th centile for
homocysteine in men and women in the United States
27),
background fortification, proportion of study participants with
diabetesatbaseline(moreorlessthantheapproximatemedian),
proportionofstudyparticipantswithcardiacdiseaseatbaseline
(moreorlessthantheapproximatemedian),whethertheoverall
study population was recruited on the basis of kidney disease,
average follow-up time (more or less than the approximate
median, 30 months), study event number (more or less than the
approximatemedian,150events),andcompositedefinition(the
prespecified definition of myocardial infarction, stroke, or
cardiovascular death, or other definition according to the study
authors).
We considered a P value of less than 0.05 as significant for all
analyses. Statistical analyses were carried out with Stata 11.0
(Stata; TX, USA).
Results
The search yielded 359 articles, of which 36 were reviewed in
fulltext(fig1⇓).Elevenrandomisedtrialsprovidedinformation
on 10 951 participants with kidney disease, totalling 4389 with
stage 3-4 chronic kidney disease, 2452 with end stage kidney
disease, and 4110 with functioning kidney transplants (table⇓).
Trials were reported between 2004 and 2011, with additional
data provided by the authors for one study.
8 Trial participants
consisted entirely of people with end stage kidney disease for
four trials,
6 9 28 29 both end stage kidney disease and chronic
disease in two trials,
7 8 and people with a functioning kidney
transplant in one trial.
22 Three papers reported on subgroups of
chronic kidney disease from larger trials of vascular disease or
diabetes,
30 survivors of myocardial infarction,
31 and survivors
of stroke or transient ischaemic attack,
32 where chronic kidney
disease was defined as an estimated glomerular filtration rate
of less than 60 ml/min
30 31 or a serum creatinine concentration
greater than 120 µmol/L.
32 One trial was carried out in people
withdiabeticnephropathy,definedasthecoexistenceofdiabetes
and albuminuria (minimum 300 mg/day) or proteinuria
(minimum500mg/day).
33Onetrialwasexcludedasitcompared
two different methods of homocysteine lowering therapy (50
mg intravenous 5-methyltetrahydrofolate three times a week
comparedwith5mgoralfolicaciddaily)ratherthancomparing
with placebo or comparing different dose intensities.
34
The mean age of trial participants was between 48.5 and 72.2
years(table).Theproportionoftrialparticipantswhoweremale
ranged from 50% to 98% (median 64%), the proportion with a
diagnosisofdiabetesrangedfrom11%to100%(median40%),
andtheproportionwithahistoryofcardiacdiseaserangedfrom
11% to 100% (median 34%). Follow-up ranged from 24 to 60
months (median 38 months, table).
Baseline homocysteine levels were increased at baseline and
were reduced by folic acid based therapy (table). The mean
difference in homocysteine levels between treated and control
participantswas−4.97µmol/L(95%confidenceinterval−9.44
to −0.49) in the five studies reporting the requisite data for the
calculation.
8 9 22 30 33 Homocysteine levels were reduced into the
normal range (≤12 µmol/L) in only two studies, both of which
were carried out in populations with milder degrees of renal
dysfunction.
22 30
The interventions were predominantly based on daily oral folic
acid supplementation in doses of between 2.5 mg and 40 mg
(table).CointerventionsincludedsupplementationwithBgroup
vitamins(seventrials,9852participants).Seventrialscompared
an intervention with placebo, one compared an intervention
withusualcare(noplacebo),andthreecomparedanintervention
with low dose vitamins (table). One trial consisted of a three
way comparison of high (15 mg), medium (5 mg), and low (1
mg)dosedailyoralfolicacidsupplementation.
6Forthepurposes
of the current analysis the high and medium dose arms were
combined and compared with the low dose arm. One trial that
recruited people with a functioning kidney transplant reported
bothanalysesonoutcomescensoredthreemonthsafterthestart
ofdialysisandoutcomesofintentiontotreatanalyses,
22ofwhich
the intention to treat analyses were selected for our review.
Baseline mean homocysteine levels ranged from 15.6 to 47
µmol/L.Fivetrialsreportedachievedmeanhomocysteinelevels,
which ranged from 11.9 to 22.6 µmol/L in the intervention
group. Four trials were done on a background of fortification
of grain with folic acid, whereas one was done with partial
fortification of grain.
Effect of homocysteine lowering therapy on
outcomes
Cardiovascular events
Ten studies reported 3045 cardiovascular events among 10 863
participants (fig 2⇓). Homocysteine lowering therapy had no
overall effect on cardiovascular events (relative risk 0.97, 95%
confidence interval 0.92 to 1.03, P=0.326). There was no
evidenceofheterogeneityacrosstheincludedstudies(I
2=0.0%,
P=0.467 for heterogeneity).
Supplementary figure 2 shows the effects on secondary
outcomes.Homocysteineloweringdidnotaffectcardiovascular
mortality (six trials, 5968 participants, relative risk 0.97, 95%
confidence interval 0.82 to 1.16, supplementary figure 3), all
causemortality(ninetrials,8772participants,1.020.95to1.10,
supplementary figure 4), myocardial infarction (eight trials,
8586 participants, 0.96, 0.84 to 1.11, supplementary figure 5),
or stroke (eight trials, 8586 participants, 0.95, 0.75 to 1.21,
supplementary figure 6), with no heterogeneity overall or
between different categories of kidney disease.
Homocysteineloweringdidnotaffectratesofaccessthrombosis
(three trials, relative risk 0.96, 95% confidence interval 0.83 to
1.11, supplementary figure 7). In addition, homocysteine
lowering therapy did not reduce rates for start of renal
replacement therapy in people with non-dialysis dependent
chronic kidney disease (two studies, 1543 participants, relative
risk1.05,95%confidenceinterval0.95to1.16)orafunctioning
kidney transplant (one study, 4110 participants, 1.12, 0.91 to
1.37, supplementary figure 8).
Tolerability of homocysteine lowering agents
Adverseeventrateswerereportedbyseventrials(supplementary
figure9).Homocysteineloweringhadnoeffectonadverseevent
rates (relative risk 1.00, 95% confidence interval 0.92 to 1.08,
P=0.93). The rates of reported adverse events varied noticeably
between studies, ranging from 1.8% (adverse events leading to
withdrawal from study treatment)
6 to 89.1% (adverse events
including “many transient minor complaints, such as dizziness,
nausea or headache”).
33 Some trials reported only
malignancies.
9 30 We were unable to complete planned separate
analyses of gastrointestinal, dermatological, neurological, and
malignant events owing to the small number of trials reporting
these outcomes.
Subgroup analyses
The impact of folic acid based homocysteine lowering on
cardiovascular events did not differ significantly in any of the
subgroups studied (fig 3⇓). Patient characteristics examined
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RESEARCHincluded kidney disease classification (P=0.785 for
heterogeneity), baseline homocysteine levels (P=0.368 for
heterogeneity), the proportion with diabetes (P=0.346 for
heterogeneity),andtheproportionwithcardiacdisease(P=0.741
for heterogeneity). Trial characteristics studied included the
intervention (use of folic acid compared with folic acid plus B
group vitamins: P=0.568 for heterogeneity), the type of study
(primarychronickidneydiseaseversussubgroupoflargerstudy:
P=0.877forheterogeneity),theaveragefollow-uptime(P=0.342
for heterogeneity), the number of events in the study (P=0.637
heterogeneity), and the use of a predefined cardiovascular
composite endpoint (P=0.815 for heterogeneity). The effect of
any exposure to folic acid in the controls was assessed through
background folic acid fortification in the studied population
(P=0.121 for heterogeneity) and through any exposure either
by background fortification or by trial administered low dose
folic acid (P=0.204 for heterogeneity). Continuous variables
(baseline homocysteine levels, trial proportion with diabetes,
trial proportion with cardiac disease, average follow-up time,
and number of events in the study) were also explored using
metaregression in sensitivity analyses, with results confirming
thatnoneofthesefactorshadasignificantimpactontheoverall
meta-analysis (results not shown).
Quality
Trialswereoverallofhighquality(supplementarytable1)with
the method of sequence generation clear in eight of the 11
studies and explicit details of allocation concealment in 10
studies. Participants, study staff, and outcome assessors were
blinded in 10 studies. There was low risk of bias as a result of
outcome reporting and selective outcome reporting in all 11
trials. Evidence of small study publication bias was lacking
(Harbord test P=0.850).
Discussion
In this large systematic review including over 10 000
participants with kidney disease, randomisation to folic acid
based homocysteine lowering therapy did not affect the
incidence of cardiovascular events, all cause mortality,
cardiovascular mortality, myocardial infarction, stroke,
requirement for dialysis treatment, or access thrombosis. There
was no evidence of harm, defined by rates of adverse events in
people with kidney disease, although this conclusion should
perhaps be interpreted with caution given the noticeable
variation in definitions and rates of adverse events reported in
the trials. These outcomes were consistent across categories of
kidneydisease(endstagekidneydisease,chronickidneydisease,
and functioning kidney transplant), with no evidence of
heterogeneity. Many people with kidney disease seem to be
receiving folic acid supplementation
35 and some guidelines
recommendsupplementationoffolicacidandBgroupvitamins
or of water soluble vitamins in people with kidney disease on
prudentialgrounds.
36 37Ourfindingssuggestthatfolicacidbased
homocysteine lowering therapy should not be used for the
prevention of cardiovascular events in people with kidney
disease, a population in whom drug burden is often high.
Comparison with systematic reviews of
homocysteine lowering in all populations
Thesedataareconsistentwithstudiesinthegeneralpopulation,
wherefolicacidbasedhomocysteineloweringhasalsonotbeen
found to prevent cardiovascular events in large randomised
trials. Previous systematic reviews have analysed the effect of
folicacidbasedhomocysteineloweringinthegeneralpopulation
assuccessivetrialshavebeenreported.In2006,ameta-analysis
of 12 randomised trials reported no effect on the risk of
cardiovascular disease, coronary heart disease, stroke, or all
causemortality.
15Thepossibilityofbenefitforstrokeoutcomes
was raised in 2007 in a meta-analysis of eight trials (relative
risk 0.82, 95% confidence interval 0.68 to 1.00, P=0.045).
38
More recently, the VITATOPS trial carried out in people with
recent stroke or transient ischaemic attack found no significant
effect on cardiovascular events (relative risk 0.91, 95%
confidence interval 0.82 to 1.00, P=0.05) or stroke (0.92, 0.81
to 1.06).
32 The addition of the VITATOPS results to those of
previous studies again found no reduction in cardiovascular
events, stroke (0.94, 0.86 to 1.01), or myocardial infarction.
32
An individual patient meta-analysis was published by the
B-VitaminTreatmentTrialists’Collaborationin2010of37485
participants in eight trials randomised to folate containing B
vitamins or to control for the prevention of vascular disease.
20
The meta-analysis showed that folic acid supplementation had
no impact on major vascular events, mortality, or cancer
incidence despite an average 25% reduction in homocysteine
levels. There was no evidence of heterogeneity in subgroup
analyses comparing the impact of the intervention according to
serum creatinine concentrations (<80, 80-94, and ≥95 µmol/l).
The trialists’ analysis included 4361 participants contained in
the current analysis, representing 12% of the individual patient
datameta-analysisand40%ofthecurrentreport.Theadditional
6590participantsincludedinthecurrentreportarefromstudies
published after the previous report (4603 participants) or from
studies that did not meet the 1000 participant criteria of the
formerreport(1987participants).Thesestudieshaveeffectively
excluded any beneficial cardiovascular effect of homocysteine
lowering therapy in the general population, and the current
reviewaddstothisevidencebysimilarlyexcludingmeaningful
benefit in kidney disease.
Comparison with previous systematic reviews
of homocysteine-lowering in people with
kidney disease
A previous systematic review of folic acid based homocysteine
lowering in people with advanced or end stage kidney disease
reported a reduction in all fatal and non-fatal cardiovascular
events (seven trials, 3886 participants, relative risk 0.85; 95%
confidence interval 0.76 to 0.96; P=0.009) and no significant
reduction in a composite of myocardial infarctions, stroke, and
cardiovascular death (five trials, 3619 participants, 0.87, 0.75
to 1.00, P=0.06), with the point estimate favouring the
intervention but with some imprecision.
39 Differences between
the analyses include the near threefold higher number of
participants in the current review (10 951 in 11 trials compared
with 3886 in seven trials in the previous analysis) through the
inclusion of all kidney disease categories, permitting a broader
study population. Our study included all reports of outcomes
for patients with kidney disease randomised to homocysteine
lowering to comprehensively summate the available evidence,
permitting the inclusion of the post hoc analysis of HOPE-2.
30
Additionally the two studies had methodological differences.
The previous meta-analysis summated the separate reports for
various cardiovascular outcomes (for example, myocardial
infarction, stroke, sudden cardiac death) to derive a figure for
acompositeofnon-fatalmyocardialinfarction,non-fatalstroke,
ordeathfromcardiovascularcauseresultinginthepotentialfor
some participants to contribute to the outcome more than once.
In our analysis we elected to use the trial definition where this
study’s composite was not reported. The different approach to
the treatment of the composite accounts for most of the
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RESEARCHdifference between ours and the previous report, with the risk
ratiofallingfrom0.972(95%confidenceinterval0.902to1.047)
to0.880(0.762to1.015)inthefourstudieswherebothmethods
can be tested. We believe the findings of the current review are
likely to be a better estimate of the true effect of folic acid based
homocysteine lowering on cardiovascular outcomes. Further
information and precision could be gained from analysis of all
completed trials through the conduct of further analyses using
data at individual patient level.
Impact of folic acid on homocysteine lowering
in people with and without kidney disease
Doses of 0.8 mg of folic acid or more are required to achieve
maximal homocysteine lowering of a standardised 23%
reduction in trials of participants where folic acid dose was
compared with homocysteine reduction.
40 The addition of
vitamin B12 increased the degree of homocysteine lowering to
30%. In 25 trials of homocysteine lowering utilising 0.8 mg
folic acid or higher, homocysteine was lowered to 12 µmol/L
or less in treated participants in all but two studies, and one of
these was carried out in participants with kidney disease.
41
Conversely among the trials of the current analysis,
homocysteine levels were largely not normalised despite doses
of folic acid substantially greater than 0.8 mg being
administered, a finding that has been shown previously.
41 42 It
has been postulated that the relative resistance of patients with
endstagekidneydiseasetofolicacidbasedtherapymaybedue
toimpairedfolicacidmetabolismandimpairedfolateabsorption
as well as impaired renal clearance.
43
Observed relation of homocysteine levels with
cardiovascular events in people with kidney
disease
Adding further strength to these conclusions, earlier reports of
clearrelationsbetweenhomocysteinelevelsandcardiovascular
events in people with kidney disease
43 have been challenged by
more recent studies observing no association
44 45 or even an
inverse association.
10 A meta-analysis of observational studies
in end stage kidney disease found no association between
homocysteinelevelsandclinicaleventsinretrospectivestudies,
whereas prospective studies showed no association with all
cause mortality but a positive association with cardiovascular
events, which increased by 9% with every 5 µmol/L increase
in homocysteine levels. These observations of the risks
associated with various homocysteine levels led in part to the
generation of the “reverse epidemiology hypothesis,” which
asserts altered risk factor patterns may be confounded by the
poor nutrition and inflammatory state common in patients
requiringdialysissuchthattheassociationofhomocysteineand
outcomes is driven by nutritional state.
46 47 Another explanation
supported by some
45 48 49 but not all
5 50 51 analyses, is that
homocysteineissimplyamarkerofkidneyfunction.Regardless
ofthenatureoftheassociationreportedbyobservationalstudies,
it is now clear that interventions to lower homocysteine levels
in people with kidney disease do not lead to a reduction in
cardiovascular events.
Impact of background fortification on
homocysteine lowering
The relative risk of cardiovascular events was 0.91 (95%
confidence interval 0.81 to 1.02) in trials where controls had no
exposuretofolicacidbasedregimens,comparedwith0.99(0.93
to1.06)intrialswherecontrolsdidhavesomelevelofexposure,
either through fortification or through comparator treatment.
The difference was not significant (P=0.24 for heterogeneity).
The individual patient data meta-analysis of eight large trials
found that folic acid based therapy had no impact on major
vascular events, whether administered against a background of
fortification (relative risk 0.99 99% confidence interval 0.90 to
1.09) or not (1.02, 0.96 to 1.09).
20 Short of further randomised
trials, individual patient level data analysis of participants in all
homocysteineloweringtrialsaccordingtokidneydiseasestatus
may increase analysis power providing greater clarity.
Strengths and limitations of the review
The strengths of this systematic review are its rigorous
methodology, the importance of the clinical question, and the
clear result. The findings have direct implications for the
management of hundreds of millions of people with kidney
disease around the world, including millions receiving dialysis
forendstagekidneydisease,manyofwhomarecurrentlytaking
folic acid supplements. Limitations include the reliance on
tabular data rather than individual patient level data. Some
studies used different definitions for the primary outcome of
cardiovascular events, although this did not seem to
meaningfullyimpactthefindings.Wecouldonlyincluderesults
for people with kidney disease included in larger trials where
these are reported, raising the possibility of reporting bias.
However this would be expected to exaggerate any benefit and
none was found. Furthermore, the definition of chronic kidney
disease varied among the studies (see table).
Conclusion
In summary, folic acid based homocysteine lowering does not
preventcardiovasculareventsinpeoplewithkidneydiseaseand
consideration should be given to discontinuing its use for
cardiovascular prevention in this population.
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RESEARCHWhat is already known on this topic
Elevated homocysteine levels are associated with an increased risk of cardiovascular events
Homocysteine lowering in the general population has failed to show clear cardiovascular benefits unlike the situation with people with
homocysteinuria who have noticeably increased homocysteine levels
Homocysteine levels increase as estimated glomerular filtration rate levels decline
What this study adds
In over 10 000 people with a range of severity of kidney disease no benefit was seen from folic acid based homocysteine lowering
therapy for cardiovascular events, all cause mortality, cardiovascular mortality, myocardial infarction, stroke, requirement for dialysis
treatment, or access thrombosis
The results were consistent across categories of kidney disease (end stage kidney disease, chronic kidney disease, and functioning
kidney transplant), with no evidence of heterogeneity
Our findings suggest that folic acid based homocysteine lowering should not be used for cardiovascular prevention in people with kidney
disease
Competing interests: All authors have completed the ICMJE uniform
disclosure form at www.icmje.org/coi_disclosure.pdf (available on
request from the corresponding author) and declare that : no support
from any organisation for the submitted work; SZ is a member of the
advisory boards for MSD, Novo Nordisk, and Boehringer Ingelheim,
and has received consultancies from Novo Nordisk and Johnson and
Johnson, speakers fees from MSD, Novo Nordisk, Astra Zeneca/BMS,
Novartis, Sanofi Aventis, and Servier International, and payment for the
development of educational presentations from Medi Mark; MG has
received payment for lectures from Roche Pharmaceuticals; SDN has
received a KL2 grant from the National Institutes of Health; AC has
received payment for lectures from Roche, Servier, AMGEN, and MSD;
MJ has received an unrestricted grant from CSL; Concord Hospital has
received an educational grant from Shire; VP is a member of the Abbot
advisory board, has grants or grants pending from Roche, Johnson and
Johnson, Baxter, and Servier and has received payment for lectures
from Roche, Servier, and Astra Zeneca; MJ, AK, SZ, TN, MG, AC, and
VP are affiliated with the George Institute, which receives funding from
various pharmaceutical companies to support parts of its research
activities, which companies might have an interest in the submitted work
in the previous three years; and no other relationships or activities that
could appear to have influenced the submitted work.
Ethical approval: Not required.
Data sharing: No additional data available.
1 Lin Y-H, Pao K-Y, Wu V-C, Lin Y-L, Chien Y-F, Hung C-S, et al. The influence of estimated
creatinine clearance on plasma homocysteine in hypertensive patients with normal serum
creatinine. Clin Biochem 2007;40:230-4.
2 Nerbass FB, Draibe SA, Feiten SF, Chiarello PG, Vannucchi H, Cuppari L. Homocysteine
and its determinants in nondialyzed chronic kidney disease patients. J Am Diet Assoc
2006;106:267-70.
3 Menon V, Wang X, Greene T, Beck GJ, Kusek JW, Selhub J, et al. Homocysteine in
chronic kidney disease: effect of low protein diet and repletion with B vitamins. Kidney Int
2005;67:1539-46.
4 Winkelmayer WC, Kramar R, Curhan GC, Chandraker A, Endler G, Fodinger M, et al.
Fasting plasma total homocysteine levels and mortality and allograft loss in kidney
transplant recipients: a prospective study. J Am Soc Nephrol 2005;16:255-60.
5 Ducloux D, Motte G, Challier B, Gibey R, Chalopin JM. Serum total homocysteine and
cardiovascular disease occurrence in chronic, stable renal transplant recipients: a
prospective study. J Am Soc Nephrol. 2000;11:134-7.
6 Wrone EM, Hornberger JM, Zehnder JL, McCann LM, Coplon NS, Fortmann SP.
Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal
disease. J Am Soc Nephrol 2004;15:420-6.
7 Jamison RL, Hartigan P, Kaufman JS, Goldfarb DS, Warren SR, Guarino PD, et al. Effect
of homocysteine lowering on mortality and vascular disease in advanced chronic kidney
disease and end-stage renal disease: a randomized controlled trial. JAMA
2007;298:1163-70.
8 Zoungas S, McGrath BP, Branley P, Kerr PG, Muske C, Wolfe R, et al. Cardiovascular
Morbidity and Mortality in the Atherosclerosis and Folic Acid Supplementation Trial
(ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial. J Am Coll
Cardiol 2006;47:1108-16.
9 Righetti M, Serbelloni P, Milani S, Ferrario G. Homocysteine-lowering vitamin B treatment
decreases cardiovascular events in hemodialysis patients. [see comment]. Blood Purif
2006;24:379-86.
10 Kalantar-Zadeh K, Block G, Humphreys MH, McAllister CJ, Kopple JD. A low, rather than
a high, total plasma homocysteine is an indicator of poor outcome in hemodialysis patients.
J Am Soc Nephrol 2004;15:442-53.
11 Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on
causality from a meta-analysis. BMJ 2002;325:1202.
12 Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease
and stroke: a meta-analysis. JAMA 2002;288:2015-22.
13 Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, et al. Homocysteine
lowering and cardiovascular events after acute myocardial infarction. N Engl J Med
2006;354:1578-88.
14 Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, et al.
Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke,
myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP)
randomized controlled trial. JAMA 2004;291:565-75.
15 Bazzano LA, Reynolds K, Holder KN, He J. Effect of folic acid supplementation on risk
of cardiovascular diseases: a meta-analysis of randomized controlled trials. JAMA
2006;296:2720-6.
16 Mei W, Rong Y, Jinming L, Yongjun L, Hui Z. Effect of homocysteine interventions on the
risk of cardiocerebrovascular events: a meta-analysis of randomised controlled trials. Int
J Clin Pract 2010;64:208-15.
17 Yap S. Classical homocystinuria: vascular risk and its prevention. J Inherit Metab Dis
2003;26:259-65.
18 Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, et al. Homocysteine lowering
with folic acid and B vitamins in vascular disease. N Engl J Med 2006;354:1567-77.
19 Heinz J, Kropf S, Luley C, Dierkes J. Homocysteine as a risk factor for cardiovascular
disease in patients treated by dialysis: a meta-analysis. Am J Kidney Dis 2009;54:478-89.
20 Clarke R, Halsey J, Lewington S, Lonn E, Armitage J, Manson JE, et al. Effects of lowering
homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific
mortality: meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern
Med 2010;170:1622-31.
21 Moher D, Liberati A, Tetzlaff J, Altman DG, The PG. Preferred Reporting Items for
Systematic Reviews and Meta-Analyses: the PRISMA statement. PLoS Med
2009;6:e1000097.
22 Bostom AG, Carpenter MA, Kusek JW, Levey AS, Hunsicker L, Pfeffer MA, et al.
Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant
recipients: primary results from the folic acid for vascular outcome reduction in
transplantation trial. Circulation 2011;123:1763-70.
23 JPT Higgins, Green S (eds). Cochrane handbook for systematic reviews of interventions
version 5.1.0 [updated March 2011]. Cochrane Collaboration, 2011.
24 Harbord RM, Egger M, Sterne JAC. A modified test for small-study effects in meta-analyses
of controlled trials with binary endpoints. Stat Med 2006;25:3443-57.
25 Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a
simple, graphical test. BMJ 1997;315:629-34.
26 Woodward M. Epidemiology: study design and data analysis. 2nd ed. Chapman and
Hall/CRC Press, 2005.
27 Ganji V, Kafai MR. Population reference values for plasma total homocysteine
concentrations in US adults after the fortification of cereals with folic acid. Am J Clin Nutr
2006;84:989-94.
28 Heinz JM, Kropf SP, Domrose UMD, Westphal SMD, Borucki KMD, Luley CMD, et al. B
vitamins and the risk of total mortality and cardiovascular disease in end-stage renal
disease: results of a randomized controlled trial. [Article]. Circulation 2010;121:1432-8.
29 Vianna ACA, Mocelin AJ, Matsuo T, Morais-Filho D, Largura A, Delfino VA, et al. Uremic
hyperhomocysteinemia: a randomized trial of folate treatment for the prevention of
cardiovascular events. Hemodial Int 2007;11:210-6.
30 Mann JFE, Sheridan P, McQueen MJ, Held C, Arnold JMO, Fodor G, et al. Homocysteine
lowering with folic acid and B vitamins in people with chronic kidney disease—results of
the renal Hope-2 study. Nephrol Dial Transplant 2008;23:645-53.
31 Armitage JM, Bowman L, Clarke RJ, Wallendszus K, Bulbulia R, Rahimi K, et al. Effects
of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and
major morbidity in myocardial infarction survivors: a randomized trial. JAMA
2010;303:2486-94.
32 The VITATOPS Trial Study Group. B vitamins in patients with recent transient ischaemic
attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised,
double-blind, parallel, placebo-controlled trial. Lancet Neurol 2010;9:855-65.
33 House A, Eliasziw M, Cattran D, Churchill D, Oliver M, Fine A, et al. Effect of B-vitamin
therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA
2010;303:1603-9.
34 Cianciolo G, La Manna G, Coli L, Donati G, D’Addio F, Persici E, et al.
5-methyltetrahydrofolate administration is associated with prolonged survival and reduced
inflammation in ESRD patients. Am J Nephrol 2008;28:941-8.
35 Andreucci VE, Fissell RB, Bragg-Gresham JL, Ethier J, Greenwood R, Pauly M, et al.
Dialysis Outcomes and Practice Patterns Study (DOPPS) data on medications in
hemodialysis patients. Am J Kidney Dis 2004;44(5 suppl 2):61-7.
36 KDOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients: section
III. State of the science: novel and controversial topics in cardiovascular diseases. NFK
KDOQI Guidelines, 2005. www.kidney.org/professionals/kdoqi/guidelines_cvd/homocystein.
htm.
37 Holt S, Goldsmith D. Cardiovascular disease in CKD. Guidelines: UK Renal Association,
2010. www.renal.org/Clinical/GuidelinesSection/CardiovascularDiseaseInCKD.aspx#
Summary2.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:e3533 doi: 10.1136/bmj.e3533 (Published 13 June 2012) Page 6 of 11
RESEARCH38 Wang X, Qin X, Demirtas H, Li J, Mao G, Huo Y, et al. Efficacy of folic acid supplementation
in stroke prevention: a meta-analysis. Lancet 2007;369:1876-82.
39 Qin X, Huo Y, Langman CB, Hou F, Chen Y, Matossian D, et al. Folic acid therapy and
cardiovascular disease in ESRD or advanced chronic kidney disease: a meta-analysis.
Clin J Am Soc Nephrol 2011;6:482-8.
40 Homocysteine Lowering Trialists Collaboration. Dose-dependent effects of folic acid on
blood concentrations of homocysteine: a meta-analysis of the randomized trials. Am J
Clin Nutr 2005;82:806-12.
41 K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in
dialysis patients. Am J Kidney Dis 2005;45(4 suppl 3):S1-153.
42 Levey AS, Eknoyan G. Cardiovascular disease in chronic renal disease. [see comment].
Nephrol Dial Transplant 1999;14:828-33.
43 Robinson K, Gupta A, Dennis V, Arheart K, Chaudhary D, Green R, et al.
Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in
end-stage renal disease and is closely linked to plasma folate and pyridoxine
concentrations. Circulation 1996;94:2743-8.
44 Nair AP, Nemirovsky D, Kim M, Geer EB, Farkouh ME, Winston J, et al. Elevated
homocysteine levels in patients with end-stage renal disease. Mt Sinai J Med
2005;72:365-73.
45 Menon V, Sarnak MJ, Greene T, Wang X, Pereira AA, Beck GJ, et al. Relationship between
homocysteine and mortality in chronic kidney disease. Circulation 2006;113:1572-7.
46 Kopple JD. The phenomenon of altered risk factor patterns or reverse epidemiology in
persons with advanced chronic kidney failure. Am J Clin Nutr 2005;81:1257-66.
47 Suliman M, Stenvinkel P, Qureshi AR, Kalantar-Zadeh K, Barany P, Heimburger O, et al.
The reverse epidemiology of plasma total homocysteine as a mortality risk factor is related
to the impact of wasting and inflammation. Nephrol Dial Transplant 2007;22:209-17.
48 Potter K, Hankey GJ, Green DJ, Eikelboom JW, Arnolda LF. Homocysteine or renal
impairment. which is the real cardiovascular risk factor? Arterioscler Thromb Vasc Biol
2008;28:1158-64.
49 Silva de Almeida CC, Guerra DC, Vannucchi MTI, Geleilete TJM, Vannucchi H, Chiarello
PG. What is the meaning of homocysteine in patients on dialysis? J Ren Nutr
2011;21:394-400.
50 Massy ZA, Chadefaux-Vekemans B, Chevalier A, Bader CA, Drueke TB, Legendre C, et
al. Hyperhomocysteinaemia: a significant risk factor for cardiovascular disease in renal
transplant recipients. Nephrol Dial Transplant 1994;9:1103-8.
51 Connolly GM, Cunningham R, McNamee PT, Young IS, Maxwell AP. Elevated
homocysteine is a predictor of all-cause mortality in a prospective cohort of renal transplant
recipients. Nephron Clin Pract 2010;114:c5-11.
Accepted: 8 May 2012
Cite this as: BMJ 2012;344:e3533
This is an open-access article distributed under the terms of the Creative Commons
Attribution Non-commercial License, which permits use, distribution, and reproduction in
any medium, provided the original work is properly cited, the use is non commercial and
is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-
nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:e3533 doi: 10.1136/bmj.e3533 (Published 13 June 2012) Page 7 of 11
RESEARCHTable
Table 1| Characteristics of studies reporting effect of folic acid based homocysteine lowering therapy in people with kidney disease
Median
follow-up
(months)
Grain
fortification Comparison
Study
intervention‡
Meanhomocysteine*
(µmol) Components of
cardiovascular
composite
No (%)
with
cardiac
disease
No (%)
with
diabetes
%
male
Mean
age
(years)
Category
of kidney
disease
No (%)
Study
population Study Achieved† Baseline
24 Yes 1 mg folic acid 15 mg or 5 mg
folic acid daily¶
24.9 32.9 Myocardial
infarction, stroke,
death, coronary
revascularisation,
transient
ischaemic attack,
174 (34)§ 232 (45) 50 60.2 ESKD 510
(100)
ESKD Wrone 2004
6
carotid
endarterectomy,
amputation
43 No Placebo 15 mg folic acid 21.5‡‡ 27 Myocardial
infarction, stroke,
cardiovascular
death
35 (11)†† 73 (23) 68 56.2 ESKD 267
(85); CKD
48 (15)**
ESKD and CKD Zoungas 2006
8
(ASFAST)
29 No Usual care Folic acid 5 mg
daily or 2nd
daily according
to folic acid
levels+vitamin
B complex 2nd
22.6 34.6 Myocardial
infarction, stroke,
sudden cardiac
death, angina,
carotid
endarterectomy in
51 (58)§ 17 (19) 56 64.6 ESKD 88
(100)
ESKD (HD) Righetti 2006
9
daily (B1 250 patients with
symptoms§§ mg, B6 250 mg,
B12 500 mg) if
plasma B12
depleted
38 Yes Placebo 40 mg folic
acid, 100 mg
vitamin B6, 2mg
vitamin B12
daily
17.8 24.1 Myocardial
infarction, stroke,
all cause
mortality,
amputation
511 (25)†† 1129 (55) 98 65.8 ESKD 751
(37); CKD
1305
(63)¶¶
ESKD and CKD Jamison 2007
7
(HOST)
24 No Placebo 10 mg folic acid
3 times per
week after
haemodialysis
NR 25.0‡‡ Myocardial
infarction, stroke,
cardiovascular
death,
arrhythmias,
angina, heart
failure
44 (24)§ 42 (23) 59 48.5 ESKD 186
(100)
ESKD Vianna 2007
29
60 Partial‡‡‡ Placebo 2.5 mg folic
acid, 50 mg
vitamin B6, 1
mg vitamin B12
11.9 15.8 Myocardial
infarction, stroke,
cardiovascular
death
537 (87)§ 269 (43) 67 72.2 CKD 619
(100)†††
Vascular
disease or DM
(CKD 11%)
Mann 2008
30
(HOPE 2)***
32 Yes Placebo 2.5 mg folic
acid, 25 mg
vitamin B6, 1mg
vitamin B12
13.3 15.5 Myocardial
infarction, stroke,
all cause
mortality,
revascularisation
74 (31.1)§ 238 (100) 75 60.4 CKD 238
(100)
Diabetic
nephropathy§§§
House 2010
33
(DIVINe)
80¶¶¶**** No Placebo 2 mg folic acid,
1 mg vitamin
B12
NR NR Myocardial
infarction, stroke,
coronary heart
disease death,
revascularisation
1686
(100)††¶¶¶
1267
(11)¶¶¶
83¶¶¶ 64.2¶¶¶ CKD 1686
(100)†††
History of
myocardial
infarction
Armitage 2010
31
(SEARCH)***
25 No 0.2 mg folic
acid, 4 µg B12,
1 mg B6 after
haemodialysis
5 mg folic acid,
50 µg B12, 20
mg B6 after
haemodialysis
18.8 29 Myocardial
infarction, stroke,
sudden cardiac
death, unstable
angina,
revascularisation,
312 (48) 262 (40) 58 61.0 ESKD 650
(100)
ESKD Heinz 2010
28
peripheral arterial
disease,
pulmonary
embolism,
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:e3533 doi: 10.1136/bmj.e3533 (Published 13 June 2012) Page 8 of 11
RESEARCH(continued)
Median
follow-up
(months)
Grain
fortification Comparison
Study
intervention‡
Meanhomocysteine*
(µmol) Components of
cardiovascular
composite
No (%)
with
cardiac
disease
No (%)
with
diabetes
%
male
Mean
age
(years)
Category
of kidney
disease
No (%)
Study
population Study Achieved† Baseline
thromboses
excluding shunt
thromboses
41¶¶¶ Partial‡‡‡ Placebo 2 mg folic acid,
25 mg vitamin
B6, 0.5 mg
vitamin B12
NR NR Myocardial
infarction, stroke,
cardiovascular
death
598
(7)‡‡¶¶¶
1899
(24)¶¶¶
64¶¶¶ 62.6¶¶¶ CKD 493
(100)††††
Stroke or TIA in
preceding 7
months
Hankey 2010
32
(VITATOPS)***
48¶¶¶ Yes 1.4 mg B6, 2.0
µg B12
5 mg folic acid,
50 mg B6, 1 mg
B12
11.8‡‡‡‡ 16.4 Myocardial
infarction, stroke,
cardiovascular
disease death,
resuscitated
sudden death,
820 (20.0)§ 1663
(40.5)
63 52 KTR 4110
(100)
Kidney
transplant
recipients
Bostom 2011
22
(FAVORIT)
revascularisation,
above ankle
amputation, repair
of abdominal
aortic aneurysm
CKD=predialysis chronic kidney disease; ESKD=dialysis dependent end stage kidney disease; KTR=functioning kidney transplant recipient; NR:=not reported.
*Homocysteine levels not included if not available for subgroup with chronic kidney disease.
†In intervention group.
‡Daily unless stated otherwise.
§Cardiac disease as defined by study author.
¶Study design had two intervention arms and one “standard care” arm. For the current analysis, two intervention arms are combined.
**Non-dialysis dependent chronic kidney disease, defined as serum creatinine concentration ≥0.4 mmol/L.
††Cardiac disease defined as previous myocardial infarction.
§§Cardiovascular composite not reported separately for randomised and observed participants.
¶¶Chronic kidney disease defined as Cockcroft-Gault estimated glomerular filtration rate ≤30 ml/min.
‡‡Median reported.
***Chronic kidney disease subgroup of larger trial.
†††MDRD estimated glomerular filtration rate <60 ml/min. Participants with severe renal disease (serum creatinine level >2× upper limit of normal) were excluded by design.
‡‡‡Grain fortification in some but not all trial countries.
§§§Participants with chronic kidney disease stage 4 and 5 were excluded by design.
¶¶¶Data for chronic kidney disease subgroup not available, data for total study reported.
****Mean reported.
††††Chronic kidney disease defined as serum creatinine concentration >120 µmol/L.
‡‡‡‡Based on a sample of 72 participants in the intervention group.
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Fig 1 Identification process for eligible studies
Fig 2 Effect of folic acid based homocysteine lowering therapy on composite cardiovascular events
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RESEARCHFig 3 Subgroup analyses for effect of homocysteine lowering on cardiovascular events. Data reported as ‘”not available”
applied to chronic kidney disease subgroups of relevant studies
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